A Phase 2 interventional study of gemcitabine and mitoxantrone in Relapsed or Refractory Mantle Cell Lymphoma (MCL), sponsored by US Oncology Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gemcitabine in Lymphoma, Mantle-Cell — none open to participants now, none under way, none of them phase 3. Gemcitabine · Lymphoma, Mantle-Cell.
Among the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2004, is one of 6 in phase 2, and was the 9th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →None of the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7
First in 1998; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 30 across the 10 interventional studies. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Sarah Cannon Research Institute has 1 study filed under Lymphoma, Mantle-Cell — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
This study's enrollment of 16 is below the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Browse Lymphoma, Mantle-Cell studies →US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
First submitted before US Oncology Research became part of Sarah Cannon Research Institute.
Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
Drug: gemcitabine · Drug: mitoxantrone · Drug: rituximab
900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
Also known as: Gemzar
Novantrone 10 mg/m2on Day 1. The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
Also known as: Novantrone
Rituxan 375 mg/m2 on Day 1. The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
Also known as: Rituxan
Objective Response Rate (CR + PR)
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: 2 years
Duration of Response
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 33 months.
Overall Survival (OS) Rate at 1 Year
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
Time frame: 1 year.
Progression-free Survival Rate at 1 Year.
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Time frame: 1 year.
| Milestone | Gemzar + Novantrone + Rituxan |
|---|---|
| Started | 16 |
| Completed | 9 |
| Not completed | 7 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Patient request | 1 |
| Withdrew: Investigator request | 1 |
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
| percentage of participants | Gemzar + Novantrone + Rituxan |
|---|---|
| Objective Response Rate (CR + PR) | 46.7 (21.3 to 73.4) |
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
| months | Gemzar + Novantrone + Rituxan |
|---|---|
| Duration of Response | 7.9 (4.8 to 31.3) |
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
| Probability of Survival | Gemzar + Novantrone + Rituxan |
|---|---|
| Overall Survival (OS) Rate at 1 Year | 0.57 (0.28 to 0.78) |
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
| Probability of Progression-free Survival | Gemzar + Novantrone + Rituxan |
|---|---|
| Progression-free Survival Rate at 1 Year. | 0.54 (0.24 to 0.77) |
Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemzar + Novantrone + Rituxan | — | 4/15 (26.7%) | 15/15 (100%) |
| Event | Gemzar + Novantrone + Rituxan |
|---|---|
| FEVERGeneral disorders | 2/15 |
| CACHEXIAGeneral disorders | 1/15 |
| PAIN ABDOGastrointestinal disorders | 1/15 |
| Event | Gemzar + Novantrone + Rituxan |
|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 15/15 |
| ASTHENIAGeneral disorders | 14/15 |
| ANEMIABlood and lymphatic system disorders | 13/15 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 12/15 |
| LEUKOPENIABlood and lymphatic system disorders | 9/15 |
| NAUSEAGastrointestinal disorders | 9/15 |
| ANOREXIAGastrointestinal disorders | 7/15 |
| CONSTIPGastrointestinal disorders | 6/15 |
| ALOPECIASkin and subcutaneous tissue disorders | 3/15 |
| DIZZINESSNervous system disorders | 3/15 |
ITT population
| Age, Continuous(years) | Gemzar + Novantrone + Rituxan |
|---|---|
| Mean | 68 ± 12.3 |
| Sex: Female, Male(Participants) | Gemzar + Novantrone + Rituxan |
|---|---|
| Female | 5 |
| Male | 11 |
| Race/Ethnicity, Customized(participants) | Gemzar + Novantrone + Rituxan |
|---|---|
| Caucasian | 16 |
| Region of Enrollment(participants) | Gemzar + Novantrone + Rituxan |
|---|---|
| United States | 16 |
No study locations are listed for this record.
The record gives a start of Dec 2004, a primary completion of Jan 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 9 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Mitoxantrone · Rituximab